Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis

被引:9
|
作者
Concha-Velasco, Fatima [1 ,2 ]
Gonzalez-Lagos, Elsa [1 ,2 ]
Seas, Carlos [1 ,2 ,3 ]
Bustamante, Beatriz [1 ,3 ]
机构
[1] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru
[2] Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru
[3] Hosp Cayetano Heredia, Dept Enfermedades Infecciosas Trop & Dermatol, Lima, Peru
来源
PLOS ONE | 2017年 / 12卷 / 03期
关键词
HIGH-DOSE FLUCONAZOLE; EARLY FUNGICIDAL ACTIVITY; AMPHOTERICIN-B; RANDOMIZED-TRIAL; COMBINED COHORT; FUNGAL BURDEN; COMBINATION; AIDS; MORTALITY; FLUCYTOSINE;
D O I
10.1371/journal.pone.0174459
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction The first-line combination therapy for HIV-associated cryptococcal meningitis (CM), a condition of high mortality particularly in the first two weeks of treatment, consists of amphotericin B plus flucytosine (5-FC). Given that 5-FC remains unavailable in many countries, the knowledge of factors influencing mycological clearance in patients treated with second-line therapy could contribute to effective management. Objectives To determine the factors associated with the clearance of Cryptococcus sp. from the cerebrospinal fluid by the second week of effective antifungal therapy (early mycological clearance) in HIV-associated CM. Methods 0Retrospective cohort study based on secondary data corresponding to HIV-associated CM cases hospitalized at a tertiary health care center in Lima, Peru where 5-FC remains unavailable. Risk factors associated with early mycological clearance were analyzed by generalized linear regression models. Results From January 2000 to December 2013, 234 individuals were discharged with a diagnosis of HIV-associated CM; in 215 we retrieved the required data. The inpatient mortality was 20% (43/215), 15 of them in the first two weeks of treatment. In the final model (157 cases), adjusted for age, previous episode of CM, ART use, type of antifungal treatment, raised intracranial pressure, frequency of therapeutic lumbar punctures, baseline fungal burden and treatment period, the factors associated with early mycological clearance were: Amphotericin B deoxycholate plus fluconazole as combination therapy (RR, 1.56; 95% CI, 1.14-2.14); severe baseline intracranial pressure (>= 35 cm H2O) (RR, 0.57; 95% CI, 0.33-0.99); and baseline fungal burden over 4.5 log(10) CFU/mL (RR, 0.61 95% CI: 0.39-0.95). Conclusions In a setting without access to first-line therapy for CM, the combination therapy with amphotericin B deoxycholate plus fluconazole was positively associated with early mycological clearance, while high fungal burden and severe baseline intracranial pressure were negatively associated, and thus related to failure.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] HIV-associated cryptococcal meningitis
    Jarvis, Joseph N.
    Harrison, Thomas S.
    AIDS, 2007, 21 (16) : 2119 - 2129
  • [2] Sertraline for HIV-associated cryptococcal meningitis
    Veringa, Anette
    van der Elst, Kim C. M.
    Day, Jeremy N.
    Thwaites, Guy E.
    Alffenaar, Jan-Willem C.
    LANCET INFECTIOUS DISEASES, 2016, 16 (10): : 1111 - 1111
  • [3] Management of HIV-Associated Cryptococcal Meningitis
    Matthew R. Osborn
    Andrej Spec
    Patrick B. Mazi
    Current Fungal Infection Reports, 2023, 17 : 124 - 131
  • [4] Management of HIV-Associated Cryptococcal Meningitis
    Osborn, Matthew R. R.
    Spec, Andrej
    Mazi, Patrick B. B.
    CURRENT FUNGAL INFECTION REPORTS, 2023, 17 (02) : 124 - 131
  • [5] Treatment for HIV-associated cryptococcal meningitis
    Tenforde, Mark W.
    Shapiro, Adrienne E.
    Rouse, Benjamin
    Jarvis, Joseph N.
    Li, Tianjing
    Eshun-Wilson, Ingrid
    Ford, Nathan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (07):
  • [6] Failure of Early Mycological Clearance in HIV-Negative Cryptococcal Meningitis
    Su, Zhihui
    Luo, Chongliang
    Dai, Kai
    Yuan, Dasen
    Qin, Bang-e
    Gu, Meifeng
    Liu, Junyu
    Chen, Yong
    Peng, Fuhua
    Jiang, Ying
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (04):
  • [7] Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
    Beardsley, J.
    Wolbers, M.
    Kibengo, F. M.
    Ggayi, A. -B. M.
    Kamali, A.
    Cuc, N. T. K.
    Binh, T. Q.
    Chau, N. V. V.
    Farrar, J.
    Merson, L.
    Phuong, L.
    Thwaites, G.
    Van Kinh, N.
    Thuy, P. T.
    Chierakul, W.
    Siriboon, S.
    Thiansukhon, E.
    Onsanit, S.
    Supphamongkholchaikul, W.
    Chan, A. K.
    Heyderman, R.
    Mwinjiwa, E.
    van Oosterhout, J. J.
    Imran, D.
    Basri, H.
    Mayxay, M.
    Dance, D.
    Phimmasone, P.
    Rattanavong, S.
    Lalloo, D. G.
    Day, J. N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (06): : 542 - 554
  • [8] Emerging concepts in HIV-associated cryptococcal meningitis
    Lawrence, David S.
    Boyer-Chammard, Timothee
    Jarvis, Joseph N.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2019, 32 (01) : 16 - 23
  • [9] Forgotten but not gone: HIV-associated cryptococcal meningitis
    Jarvis, Joseph N.
    Harrison, Thomas S.
    LANCET INFECTIOUS DISEASES, 2016, 16 (07): : 756 - 758
  • [10] Immune correlates of HIV-associated cryptococcal meningitis
    Tenforde, Mark W.
    Scriven, James E.
    Harrison, Thomas S.
    Jarvis, Joseph N.
    PLOS PATHOGENS, 2017, 13 (03)